MK0859 Dose-Ranging Study (0859-003)

Phase 2

Terminated

• Conditions: Hypercholesterolemia; Mixed Hyperlipemia

• Registration Number: NCT00325455
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

To assess the cholesterol changing effects of MK0859 in patients with primary hypercholesterolemia or mixed dyslipidemia.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2006-05-11
• Study First Submitted QC: 2006-05-11
• Study First Posted: 2006-05-12
• Study Start: 2006-06
• Primary Completion: 2007-02
• Study Completion: 2007-03
• Status Verified: 2015-02
• Last Update Submitted: 2015-02-27
• Last Update Posted: 2015-03-02

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• Eligible patients will be men and women of non-child bearing potential, 18 through 75 years of age diagnosed with high cholesterol

Exclusion Criteria

• Patients with CHD or CHD-equivalent disease (except diabetes)
• Diabetics on statins

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
To assess the cholesterol changing effects of MK0859

Secondary Outcome Measures

Name	Time	Method
Acceptable safety profile